Source: Med-X StartEngine Page
Med-X, Inc. COO Matt Mills discusses discusses the end of the Malibu Brands Pacific Pain Relief Cream Indiegogo campaign as well as the end of our current Regulation A+ offering coming in 11 days.
<iframe width="560" height="315" src="https://www.youtube.com/embed/JFulhMm3cEk" frameborder="0" allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe>
A special thank you goes out to all of our shareholders and supporters who backed the Indiegogo launch of the Malibu Brands new pain cream product. Today we shipped out orders to over 200 backers. You should have received an email with your tracking information. If you did not get an email with your tracking info let us know and we will send it over to you. Everything is going out Priority Mail so you should see it early next week. When you get it please let us know!
In the coming weeks, we plan to follow up with the group of first backers so we can get your feedback on the product. Sharing your stories is going to be critical as we roll this out to retailers. We are currently in talks with a couple of retail product brokers as well as our current relationships with distributors and OTC pharmacy buyers.
If you were not able to participate in the launch and you would still like to get a jar you can order it directly from the website.
As you saw in the video, Matthew explains that as of today there are only 11 days left on our current Regulation A+ offering. On June 29th this offering will expire. If you have questions about this please make sure to call your company representative or contact us via email or phone. Below is a link to our latest filing with the Securities Exchange Commission.
https://www.sec.gov/Archives/edgar/data/1620704/000147793219003131/medx_1a.htm
Thanks again to everyone who participated in the cream launch as well as the continued support from all of our shareholders.
818-349-2870
Have a great weekend and Happy Fathers Day to all the Fathers in our shareholder group!
No Offer or Solicitation Securities
This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.
Med-X, Inc. Cautionary Statement Regarding Forward-Looking Statements
There may be statements in this communication that are, or could be, "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and, therefore, subject to risks and uncertainties, including, but not limited to, statements regarding Med-X, Inc. or the combined company's future financial position, sales, costs, earnings, cash flows, other measures of results of operations, capital expenditures or debt levels are forward-looking statements. Words such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe," "should," "forecast," "project" or "plan" or terms of similar meaning are also generally intended to identify forward-looking statements. Med-X, Inc. cautions that these statements are subject to numerous important risks, uncertainties, assumptions and other factors, some of which are beyond Med-X, Inc.'s control, that could cause Med-X, Inc. or the combined company's actual results to differ materially from those expressed or implied by such forward-looking statements. To learn more about the Risk factors, please review Med-X, Inc.'s Regulation A+ Offering Circular.